COVID-19 briefing: coronavirus impacts for UK and Ireland pharma and biotech

Overview

This April webinar is part of IQVIA’s monthly updates on the impact of COVID-19 and its implications for the healthcare ecosystem.

In the global effort to proactively fight COVID-19, the webinar series has been designed to:

• Provide some areas which pharma and biotech companies may wish to consider around the COVID-19 outbreak, in order to help guide our community through uncertain times
• Share key healthcare impact learnings from those countries that are ahead in the COVID-19 curve
• Look at how we can, together, best support patients, healthcare professionals, life sciences and governments to reduce the impact of the virus

This April webinar took place on Thursday 23^rd April from 12.30 to 13.30 (BST) / 07:30 to 08:30 (EST).

You can listen to the March webinar here.

Focus

During the April instalment, our expert panel discussed:

• Assessing the pharmaceutical market impact of COVID-19
• The UK clinical trials on COVID-19: navigating uncharted waters
• Genomics: research in the time of COVID-19
• Knowledge sharing: the COVID-19 experience from a US perspective
• Maintaining the integrity of the COVID-19 medicines supply chain

To view the webinar on demand, please click here or on the button above or below.

Our Panel

Professor Sir Mark Caulfield MD FRCP FESC FBHS FmedSci, Chief Scientist for Genomics England and Co-Director of the William Harvey Research Institute

Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension, which has discovered over 1000 gene loci for blood pressure. He served on the NICE Guideline Group for Hypertension and was President of the British Hypertension Society (2009-2011).

He was appointed Director of the William Harvey Research Institute in 2002 and was elected a Fellow of the Academy of Medical Sciences in 2008. He led on fundraising towards the £25m William Harvey Heart Centre which created a translational clinical research centre. Since 2008 he has directed the National Institute for Health Research Cardiovascular Biomedical Research Unit and Centre at Barts. Between 2010 and 2015 he co-led the merger of three hospitals in North London to create the new £400 million Barts Heart Centre which provides 80,000 cardiovascular patient episodes.

He has won the Lily Prize of the British Pharmacology Society, the Björn Folkow Award of the European Society of Hypertension 2016 and the Franz Volhard Award of the International Society of Hypertension in 2018.

In 2013 he became an NIHR Senior Investigator and was appointed as the Chief Scientist for Genomics England (100,000 Genomes Project).  He was appointed Interim Chief Executive Officer for Genomics England from January to September 2019.  Sir Mark was awarded a Knighthood in the June 2019 Queen’s Birthday Honours List for services to the 100,000 Genomes Project.

Dr Jonathan Sheffield, DHSC/NIHR COVID-19 UK Research System Operations and Liaison Director

Jonathan Sheffield was Chief Executive Officer of the National Institute for Health Research, Clinical Research Network until March 2020. He is now leading the NIHR’s response to the global pandemic in the role of DHSC/NIHR COVID-19 UK Research System Operations and Liaison Director.

The Department of Health and Social Care have been asked to manage through the NIHR research priorities of the UK’s Chief Medical Adviser and Chief Scientific Adviser as informed by SAGE.  This is being achieved through a series of platform trials to cover all phases of clinical development.

Jonathan’s task is to make this happen at pace across all NHS and care settings.  The NIHR in collaboration with the NHS across the UK has already delivered over 5000 patients into Recovery, globally the largest phase 3 study for hospitalised patients.

Carol Alexandre, Vice President, Global Accounts & Clinical Trial Supplies, IQVIA

Carol is responsible for delivering high quality information & consulting services to commercial teams of companies and organisations in the healthcare sector.  She is responsible for key relationships with suppliers and manages key global accounts. Developing services to suppliers is an intrinsic part of her role, and she has worked closely with stakeholders in the supply chain delivering customised services and commercial offerings across a range of markets.

Carol also runs the IQVIA Clinical Trial Supplies business and provides clinical supply chain services for global clinical trials.

Carol has been with IQVIA for over 20 years and her previous roles have included Market Research, Marketing, Account Management, Product Management, Data Collection, Supplier Management as well as heading up IQVIA Information business for UK & Ireland.

Nancy Dreyer, Chief Scientific Officer for Real World Evidence and SVP, IQVIA

Nancy focuses on generating high quality real-world evidence that is sufficiently reliable for regulators, clinicians, patients and payers.  Her thought leadership work includes serving as Senior Co-Editor of “Registries for Evaluating Patient Outcomes: A Users Guide” published by the US Agency for Healthcare Research and Quality, now in its 4^th edition and leader of the GRACE Principles.

Twice named in PharmaVOICE’s list of 100 most influential and inspiring individuals in life sciences, she has more than 100 publications in peer-reviewed journals and won DIA’s Global Inspire Award for Author of the Year in 2019  for “Advancing a framework for regulatory use of real world evidence: When real is reliable,” the most downloaded publication in 2018 in Therapeutic Innovation & Regulatory Science.

Nancy has 35+ years of epidemiology and business experience and holds a BA from Brandeis University as well as an MPH and PhD in Epidemiology from the University of North Carolina.

Sarah Rickwood, Vice President, European Marketing and Thought Leadership, IQVIA

Sarah Rickwood has 28 years’ experience as a consultant to the pharmaceutical industry, having worked in Accenture’s pharmaceutical strategy practice prior to joining IQVIA. She has an extremely wide experience of international pharmaceutical industry issues, having worked for most of the world’s leading pharmaceutical companies on issues in the US, Europe, Japan, and leading emerging markets. She is now Vice President, European Marketing and Thought Leadership in IQVIA, a team she has run for 10 years.

Sarah presents to hundreds of pharmaceutical industry clients every year on a wide range of global pharmaceutical industry issues, and has published white papers on many topics, including:

• Uptake and impact of innovative medicines, and challenges for Launch Excellence
• The relative strength and prognosis for the developed and the emerging pharmaceutical markets
• The global uptake and impact of multichannel marketing
• Biosimilars market opportunity and the drivers of market establishment
• Orphan drugs launch challenges
• Cell and Gene therapies commercialization challenges and opportunity
• The evolution of the global Biologics market
• Africa pharmaceutical market opportunity and challenges

Sarah holds a degree in biochemistry from Oxford University.

Moderated by Paul Tunnah, CEO, pharmaphorum

Paul Tunnah is CEO and Founder of pharmaphorum media, which facilitates productive engagement for pharma, bringing healthcare together to drive medical innovation. It combines industry-leading content and social media engagement services with the globally recognised news, information and insight portal pharmaphorum.com, working with pharmaceutical companies, service providers and broader healthcare organisations to help communicate their thought leadership and connect them with relevant stakeholders.